New migraine treatments could save $396 billion per year for US patients

24 May 2018

A new study found that if all migraine sufferers used an emerging class of preventative migraine treatments, the USA could save $396 billion in indirect costs and avoid 374 million migraine days per year, according to a posting on the website of trade group Pharmaceutical Research and Manufacturers of America, by Samantha Dougherty, a senior director of policy and research at PhRMA.

For the one in six Americans who suffer from migraine, these new therapies, called calcitonin gene-related peptide (CGRP) inhibitors, offer hope as the first medicines developed specifically for the prevention of this disease. The study found CGRP inhibitors were associated with:

Fewer hours of lost productivity per year (more than 18 per year)
Reduced need for medicines that address the symptoms of migraine
Higher probability of full-time and part-time employment
Fewer ER visits per year

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK